MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 
Similar Articles
The Motley Fool
October 20, 2009
Brian Orelli
Pfizer Starts the Blame Game Pfizer beat analysts' expectations for both revenue and adjusted earnings, but revenue was still lower than the year-ago quarter. Pfizer has excuses. mark for My Articles similar articles
The Motley Fool
January 17, 2012
Brian Orelli
You Can Forget About Seeing This Drug Work Medivation and Pfizer's Dimebon fails again. mark for My Articles similar articles
The Motley Fool
March 3, 2010
Brian Orelli
A Costly Missed Connection Dimebon's phase 3 failure costs Medivation shareholders 67%. mark for My Articles similar articles
The Motley Fool
October 21, 2008
Brian Orelli
The World Is Saving Pfizer The pharma company experienced a double-digit decrease in U.S. sales in the third quarter. Ouch. mark for My Articles similar articles
The Motley Fool
January 23, 2009
Brian Orelli
Wyeth Isn't Cheap Enough for Pfizer The Wall Street Journal reports that Pfizer is in talks to acquire Wyeth for $60 billion or more. Should they do it? mark for My Articles similar articles
The Motley Fool
October 19, 2009
Brian Orelli
Foolish Forecast: A Last Look at "Mini" Pfizer In advance of Pfizer's last earnings report before their acquisition of Wyeth, analysts expect a drop in sales and a bigger bottom line decrease. mark for My Articles similar articles
The Motley Fool
April 11, 2011
Brian Orelli
Clinical Trial Fail? Forget About It. A failure of Medivation and Pfizer's dimebon was expected. mark for My Articles similar articles
The Motley Fool
September 15, 2009
Brian Orelli
What's $115 Million Between Friends? Elan has to fix the mess it had gotten itself into with its multiple sclerosis drug Tysabri. mark for My Articles similar articles
The Motley Fool
May 12, 2009
Brian Orelli
Another Reason to Hate Big Pharma's M&A As we get closer to Pfizer and Merck wrapping up their deals, it looks like a new group is voicing their displeasure: external partners. mark for My Articles similar articles
The Motley Fool
September 30, 2009
Brian Orelli
More Questions Than Answers From Elan Things that make you go hmmm. mark for My Articles similar articles
The Motley Fool
January 28, 2010
Brian Orelli
Only the Strong Survive at Pfizer The culling of the pipeline isn't as bad as it sounds. mark for My Articles similar articles
The Motley Fool
October 30, 2009
Brian Orelli
World's Scariest Stocks: Pfizer For Pfizer, the big, scary unknown comes from whether it can integrate its recent acquisition of Wyeth. mark for My Articles similar articles
The Motley Fool
April 27, 2009
Jim Mueller
Foolish Forecast: Pfizer's Out of the Starting Gate In advance of earnings, analyst's expect revenue down 6%, but none are saying to dump the stock. mark for My Articles similar articles
The Motley Fool
December 18, 2008
Brian Orelli
Best Stock for 2009: Pfizer Pfizer's languishing stock price has made the company so much more attractive; it could see a breakout in 2009. mark for My Articles similar articles
The Motley Fool
January 29, 2010
Brian Orelli
How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years. mark for My Articles similar articles
The Motley Fool
February 22, 2007
Brian Lawler
Dueling Fools: Pfizer Bear It's been a blue chip for years, but that doesn't mean it will stay that way forever. It's inconceivable for Pfizer's market capitalization to be valued at $188 billion four years from now, when its revenues could be 40% lower than they are today. mark for My Articles similar articles
The Motley Fool
July 31, 2008
Brian Lawler
Examining Elan's Ups and Downs Was the pharmaceutical's news about its potential Alzheimer's treatment as bad as investors treated it? mark for My Articles similar articles
The Motley Fool
February 22, 2007
Ryan Fuhrmann
Dueling Fools: Pfizer Bull Rebuttal The patent expirations are an issue, but the cash is what's really important. Investors, take note. mark for My Articles similar articles
The Motley Fool
October 20, 2008
Brian Orelli
Foolish Forecast: Will Pfizer Flounder Through Another Quarter? Pharmaceutical giant Pfizer releases earnings tomorrow morning. Let's take a look at what the numbers might say and, more importantly, what management might be able to say to get this stock out of its drug-induced coma. mark for My Articles similar articles
The Motley Fool
January 26, 2009
Brian Orelli
Deja Vu All Over Again There's hardly anything to like about Pfizer's deal to buy Wyeth. This is what got Pfizer into its problem in the first place. mark for My Articles similar articles
The Motley Fool
September 5, 2008
Brian Lawler
Why Pfizer Made an Interesting Blockbuster Bet The pharma giant inked a deal worth potentially more than $725 million with development stage drugmaker Medivation to market Medivation's Alzheimer's disease drug Dimebon. mark for My Articles similar articles
The Motley Fool
December 29, 2009
Brian Orelli
Some Brand-Name Patents: Going, Going, Gone in 2010 Generic drug competition is coming for Lipitor, Plavix, and others. mark for My Articles similar articles
The Motley Fool
February 3, 2010
Brian Orelli
Wyeth Can't Save Pfizer Not much earnings growth, but the price is right. mark for My Articles similar articles
The Motley Fool
July 21, 2009
Brian Orelli
Foolish Forecast: Pfizer Meanders Toward Merger Let's look at what to expect when the pharmaceutical giant releases earnings tomorrow. mark for My Articles similar articles
The Motley Fool
April 28, 2009
Brian Orelli
The Costs of Being Pfizer With Pfizer having announced its intention to buy Wyeth this quarter, investors may have worried that the negotiating and pre-acquisition planning caused management to be distracted, but that doesn't seem to be the case. mark for My Articles similar articles
The Motley Fool
July 18, 2007
Ryan Fuhrmann
Pfizer Prepares for L-Day Will Pfizer be able to offset the looming loss of Lipitor? Investors, take note. mark for My Articles similar articles
The Motley Fool
October 20, 2006
Brian Lawler
Pfizer Keeps Fighting If Pfizer's management can succeed on its cost-savings initiatives and maintain the high single digits of earnings-per-share growth that it expects in 2007-2008, then Pfizer may make a good investment for those willing to wait for the company's new drugs to bring back higher growth. mark for My Articles similar articles
The Motley Fool
March 13, 2009
Brian Orelli
Pfizer Finally Gets a Hit! Positive results on Pfizer's cancer drug Sutent come earlier than expected. mark for My Articles similar articles
The Motley Fool
May 21, 2009
Brian Orelli
Not So Fast, Schering ... er, Merck ... er, Whoever You Are Merck got cute with its acquisition of Schering-Plough by setting up the merger so that Schering is technically merging with Merck and then changing its name to Merck. That seemingly schizophrenic move had a purpose. mark for My Articles similar articles
The Motley Fool
June 25, 2009
Brian Orelli
Pfizer Gets a Double After a couple of disappointing trials for Pfizer's Sutent, investors get some good news about the drug. mark for My Articles similar articles
The Motley Fool
January 27, 2009
Brian Orelli
Amgen's Anemic Again 2009 won't be stellar, but the future looks better. mark for My Articles similar articles
The Motley Fool
July 2, 2009
Brian Orelli
Squeezing Blood From a Half-Dollar Johnson & Johnson is investing $1 billion in Elan in exchange for an 18.4% stake in the company. mark for My Articles similar articles
The Motley Fool
February 2, 2011
Brian Orelli
Pfizer's Newest Acquisition Target The pharma giant decided to cut potential acquisitions from its revenue guidance and instead spend the money on share buybacks. mark for My Articles similar articles
Chemistry World
August 9, 2012
Bapineuzunab dropped Pfizer and Johnson and Johnson have announced that they are ending development of the intravenous Alzheimer's drug bapineuzumab after it failed in two clinical trials. mark for My Articles similar articles
The Motley Fool
December 7, 2010
Brian Orelli
How Pfizer's New Chief Can Right the Ship Bigger is not always better. mark for My Articles similar articles
The Motley Fool
January 15, 2009
Robert Steyer
For Pfizer, a Big Buy Could Be a Big Mistake Pfizer's CEO says the company must make a big, bold buy to reverse course on its skidding stock and to blast it out of its revenue doldrums. Is it the right move? mark for My Articles similar articles
The Motley Fool
June 15, 2010
Brian Orelli
Pfizer Focuses, Investors Should Cheer The culling of the pipeline continues at Pfizer. While that's bad news for partners that signed on with the company or with Wyeth before the merger it's a good move for Pfizer. mark for My Articles similar articles
The Motley Fool
August 12, 2010
Brian Orelli
Pfizer: Strengths, Weaknesses, Opportunities, Threats Knowing them all makes it easier to judge an investment. mark for My Articles similar articles
The Motley Fool
April 4, 2011
Brian Orelli
Pfizer Tests the Breakup Waters The company announced today that it found a buyer for its Capsugel unit, which will bring in a cool $2.4 billion. mark for My Articles similar articles
The Motley Fool
March 10, 2009
Brian Orelli
So Much Potential, So Little Growth In its quest to become the Johnson & Johnson of China, this purveyor of traditional Chinese medicine has been growing through acquisitions, but has paid for them through dilutive stock offerings. mark for My Articles similar articles
The Motley Fool
September 3, 2010
Brian Orelli
Why You Just Got Hammered Celldex's decline is due to potential reasons Pfizer would send back a drug it's been working on with Celldex for over two years mark for My Articles similar articles
The Motley Fool
October 22, 2009
Brian Orelli
Elan's Headed in the Right Direction Revenue up, costs down. It's a good direction for Elan to take, even if the company's final earnings number was slightly inflated. mark for My Articles similar articles
The Motley Fool
April 20, 2007
Ryan Fuhrmann
Discerning Pfizer's Pfuture The company is undergoing a transformation, but that doesn't mean it isn't worth a look from investors. mark for My Articles similar articles
The Motley Fool
June 8, 2011
Brian Orelli
Blockbuster Drug-Like Profits, No FDA Required Pfizer keeps the cuts coming. mark for My Articles similar articles
The Motley Fool
January 19, 2007
Ryan Fuhrmann
The Best Drug Stock for 2007: Pfizer Investors, this is a great company at a great price. mark for My Articles similar articles
The Motley Fool
April 21, 2008
Brian Lawler
Pfizer Is Still Floundering Generic competition keeps pounding away at its sales and profits. mark for My Articles similar articles
The Motley Fool
December 14, 2005
Steven Mallas
Pfizer: Of Drugs and Dividends Pfizer is raising its payout. Is it a good move for the drugmaker? Investors willing to hold for years while reinvesting dividends will most likely be rewarded along the way. mark for My Articles similar articles
The Motley Fool
February 10, 2006
Brian Gorman
Pfizer in Pflux The company is working on its transition, but things still look fairly murky for investors. mark for My Articles similar articles
The Motley Fool
February 29, 2008
Brian Orelli
2007 Pharma Roundup How did big pharma do in 2007? With the drug sector earnings season winding down, now seems like a good time to take a look at how they fared and, more importantly, where they're headed. mark for My Articles similar articles
The Motley Fool
February 22, 2007
Ryan Fuhrmann
Dueling Fools: Pfizer Bull The drug giant has ample firepower. The current company valuation largely ignores Pfizer's upside potential past 2008. mark for My Articles similar articles